Shares of Olympus Corp. (TYO:7733) regained more than 17 percent over the weekend after the Tokyo stock exchange indicated it might not de-list the world’s largest endoscope maker, brought low by a scheme to hide its losses with buyouts.
Insulet
Baxter CEO Parkinson cashes in, reaps $14 million | Wall Street Beat
Robert Parkinson Jr., chairman & CEO of Baxter International (NYSE:BAX), added 20 percent to his paycheck total from last year by cashing in on stock options for the first time.
Parkinson, 60, who earned $11.5 million last year, netted $14.1 million last month after exercising the options and selling stock.
Is Becton Dickinson ripe for a buyout? | Wall Street Beat
Becton Dickinson & Co. (NYSE:BDX) is at its lowest valuation since 1993, making it ripe for a buyout, after reporting dismal third-quarter results last week.
The company posted a 24 percent profit slide for the quarter Nov. 2, sending shares down 4.6 percent to a close of $72.60 that day.
Insulet misses The Street with Q3 results, lowers sales guidance | Earnings Roundup
Insulet Corp. (NSDQ:PODD) reported wider third-quarter losses than expected on Wall Street and lowered its full-year sales guidance, despite logging a 75.2 percent addition to the top line.
The Bedford, Mass.-based insulin pump maker posted losses of $13.6 million, or 29 cents per share, on sales of $44.6 million for the three months ended Sept. 30 – a 12.1 percent increase over net losses for the same period last year.
KCI CEO Burzik to transition out, senior managers to buy in | Wall Street Beat
Catherine Burzik, president, CEO and director at Kinetic Concepts Inc. (NYSE:KCI), will stay on until next summer once Apax Partners and it pension fund partners take KCI private, planned to close tomorrow.
“Ms. Burzik plans to transition her responsibilities to new leadership during 2012 before moving on to future opportunities,” according to a press release. “The terms of the program with other members of senior management include significant co-investment as well as long-term incentives.”
FLASH: BSX COO to step down by end of year | Personnel Moves
Boston Scientific Corp. (NYSE:BSX) COO Samuel Leno announced his retirement as executive VP and chief operating officer after three years with med-tech giant.
Leno made the announcement internally on Friday, Oct. 28, according to documents filed with the SEC.
Leno joined Boston Scientific in June 2007 as executive VP of finance and information systems and CFO. In March 2010, he was appointed executive VP and COO.
Medical device investment rose during Q2, even as deal volume fell | Wall Street Beat
Medical device investment deals got fatter and less frequent during the second quarter, as the value of deals grew 9 percent but their number slid 17 percent, according to PricewaterhouseCoopers.
Backers pumped $841 million into med-tech firms with 90 deals during the three months ended June 30, according to the consulting firm’s MoneyTree report. That’s up 26 percent and 3 percent, respectively, over the first quarter. The industry’s share of the venture capital cash spend on life sciences last quarter ticked down to 40 percent, however, compared with Q1 numbers.
Diabetes: Analysts bullish as Insulet makes more, spends more in Q2
Wall Street analysts believe there’s some room to grow in shares of Insulet Corp. (NSDQ:PODD), as two agencies put somewhat bullish recommendations on the maker of the Omnipod insulin pump.
Insulet, which reported a 40 percent increase in sales during the three month period ended June 30, 2011, received an upgraded outlook from Rodman & Renshaw to “market perform” in a note to investors on the Bedford, Mass.-based company.
Insulet gets a credit boost from Morningstar, but uncertainty looms
Diabetes: Analyst predicts 33 percent growth for Insulet over next three years
Insulet Corp. (NSDQ:PODD) may be headed for greener pastures over the next few years, despite increased competition from some heavy hitters in the diabetes space, according to one Wall Street analyst.
Frederick Wise, an analyst at the investment bank Leerink Swann said in a note to investors today that he came away from last week’s American Diabetes Assn. annual meeting convinced that Insulet will meet the bank’s ambitious growth numbers for the Bedford, Mass.-based company.
Diabetes device maker Insulet announces double offering
Insulet Corp. (NSDQ:PODD) has two offerings coming down the pike.
On the heels of its $63 million acquisition of Neighborhood Diabetes Inc., Insulet announced plans to offer $110 million principal amount of convertible senior notes due 2016, pursuant to SEC approval.
The Bedford, Mass.-based company will offer its underwriters an option to purchase up to another $16.5 million principal in notes to cover over-allotments.
Interest rates on the notes have not yet been defined.